BioCardia, Inc.
BCDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.07 | 0.92 | 0.16 |
| FCF Yield | -134.27% | -71.01% | -9.57% | -10.64% |
| EV / EBITDA | -0.57 | -1.23 | -8.91 | -6.96 |
| Quality | ||||
| ROIC | -447.48% | 4,057.14% | -182.47% | -103.16% |
| Gross Margin | -7,463.79% | -1,519.71% | -553.40% | 36.95% |
| Cash Conversion Ratio | 1.01 | 0.86 | 0.89 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -64.99% | -22.25% | 110.48% | 12.65% |
| Free Cash Flow Growth | 19.57% | 6.07% | -1.42% | 15.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.18 | -0.02 | 0.48 | 0.88 |
| Interest Coverage | 0.00 | 0.00 | -1,983.50 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -32.03 | 6.16 | 26.04 | -236.29 |